EUR/USD likely to find a peak near 1.25: UBS
Investing.com -- Gubra AS (CSE:GUBRA) posted record first-half results in 2025, driven by a major out-licensing deal with AbbVie (NYSE:ABBV). However, the company cut the outlook for its CRO business due to a slowdown in the U.S. market.
Gubra shares fell more than 4% in Copenhagen trading.
Revenue surged to DKK 2.5 billion from DKK 121 million a year earlier, while EBIT climbed to DKK 2.3 billion compared with a loss of DKK 21 million in the same period last year.
CEO Henrik Blou called the period “transformational, in a very positive way,” highlighting the AbbVie partnership on the company’s Amylin anti-obesity asset GUBamy.
He said the deal “really underscores Gubra’s expertise in the metabolic space” and enabled the group to distribute DKK 1 billion as an extraordinary dividend while keeping sufficient capital to pursue its strategy.
The CRO business continued to expand, though performance was mixed. Q2 revenue rose 12% year-on-year to DKK 55 million, but first-half CRO revenue fell 2% versus last year, with slower decision-making in the U.S. offsetting strong growth in Europe.
As a result, Gubra revised its 2025 CRO outlook, now guiding for revenue slightly below 2024 levels versus prior expectations of 10–20% growth.
The full-year EBIT margin forecast for the CRO unit was also lowered to around 20%, from 25–31%.